Medical expert of the article
New publications
Products of fibrinogen / fibrin degradation
Last reviewed: 23.04.2024
All iLive content is medically reviewed or fact checked to ensure as much factual accuracy as possible.
We have strict sourcing guidelines and only link to reputable media sites, academic research institutions and, whenever possible, medically peer reviewed studies. Note that the numbers in parentheses ([1], [2], etc.) are clickable links to these studies.
If you feel that any of our content is inaccurate, out-of-date, or otherwise questionable, please select it and press Ctrl + Enter.
The reference values (norm) of the plasma density in plasma are less than 10 mg / l.
The degradation products of fibrinogen / fibrin are formed in the body upon activation of the fibrinolysis system (interaction of plasmin with fibrinogen and fibrin), which develops in response to intravascular fibrin formation. The degradation products of fibrinogen / fibrin have antithromboplastin, antithrombin and antipolymerase action. Active plasmin causes a consistent asymmetric cleavage of fibrinogen / fibrin. At first, low-molecular fragments are split off from their a- and beta-chains. After their cleavage in the blood plasma remains large-molecule fragment X, which still retains the ability to form fibrin (coagulate) under the influence of thrombin. Then, under the influence of plasmin, fragment X splits into fragments Y and D, and fragment Y - into fragments D and E.
The large-molecule fragments of fibrinolysis (fragments X and Y) are called "early", and fragments D and E are "late" or finite. These fragments of fibrinogen and fibrin cleavage are called degradation products of fibrinogen / fibrin.
In a healthy person, the concentration of degradation products of fibrinogen / fibrin is extremely low. Detection of an increased content of fibrinogen / fibrin degradation products is an early diagnostic sign of DIC syndrome. Determination of fibrinogen / fibrin degradation products in blood plasma can be a diagnostic indicator of vascular occlusion, which is difficult to determine clinically. An increase in their number can occur with pulmonary thromboembolism, myocardial infarction, deep vein thrombosis, postoperative period, complications of pregnancy (placental abruption, eclampsia), in patients with various malignant neoplasms, leukemia, acute and chronic renal failure, extensive injuries, burns, shock, infectious diseases, sepsis, collagenoses, paraproteinemia, etc. Continuous detection of fibrinogen / fibrin degradation products is of great importance in diagnosing the chronic form of D BC syndrome.
[